| 1. Executive Summary |
| 2. Global Solid Tumor Market Introduction |
| 2.1. Global Solid Tumor Market - Taxonomy |
| 2.2. Global Solid Tumor Market -Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Disease Indications |
| 2.2.3. By Region |
| 3. Global Solid Tumor Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Solid Tumor Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID 19 on The Market |
| 3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
| 3.8. Mapping Market Players’ Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations, and Mergers |
| 4. Global Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Solid Tumor Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1. Antimetabolites |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. MAbs |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. XPO1 Inhibitor |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Mitotic Inhibitors |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Multikinase Inhibitors |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Antineoplastics |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Solid Tumor Market Forecast, By Disease Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1. Lung cancer |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Breast cancer |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Prostate cancer |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cervical cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Colorectal cancer |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Solid Tumor Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications, and Region, 2023 - 2029 |
| 8. North America Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 8.1.1. Antimetabolities |
| 8.1.2. MAbs |
| 8.1.3. XPO1 Inhibitor |
| 8.1.4. Mitotic Inhibitors |
| 8.1.5. Multikinase Inhibitors |
| 8.1.6. antineoplastics |
| 8.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Lung cancer |
| 8.2.2. Breast cancer |
| 8.2.3. Prostate cancer |
| 8.2.4. Cervical cancer |
| 8.2.5. Colorectal cancer |
| 8.2.6. Others |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029 |
| 8.5. North America Solid Tumor Market Dynamics - Trends |
| 9. Europe Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 9.1.1. Antimetabolities |
| 9.1.2. MAbs |
| 9.1.3. XPO1 Inhibitor |
| 9.1.4. Mitotic Inhibitors |
| 9.1.5. Multikinase Inhibitors |
| 9.1.6. antineoplastics |
| 9.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Lung cancer |
| 9.2.2. Breast cancer |
| 9.2.3. Prostate cancer |
| 9.2.4. Cervical cancer |
| 9.2.5. Colorectal cancer |
| 9.2.6. Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Italy |
| 9.3.5. Spain |
| 9.3.6. Rest of Europe |
| 9.4. Europe Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029 |
| 9.5. Europe Solid Tumor Market Dynamics - Trends |
| 10. Asia-Pacific Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.1.1. Antimetabolities |
| 10.1.2. MAbs |
| 10.1.3. XPO1 Inhibitor |
| 10.1.4. Mitotic Inhibitors |
| 10.1.5. Multikinase Inhibitors |
| 10.1.6. antineoplastics |
| 10.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Lung cancer |
| 10.2.2. Breast cancer |
| 10.2.3. Prostate cancer |
| 10.2.4. Cervical cancer |
| 10.2.5. Colorectal cancer |
| 10.2.6. Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Solid Tumor Market Dynamics - Trends |
| 11. Latin America Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.1.1. Antimetabolities |
| 11.1.2. MAbs |
| 11.1.3. XPO1 Inhibitor |
| 11.1.4. Mitotic Inhibitors |
| 11.1.5. Multikinase Inhibitors |
| 11.1.6. antineoplastics |
| 11.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Lung cancer |
| 11.2.2. Breast cancer |
| 11.2.3. Prostate cancer |
| 11.2.4. Cervical cancer |
| 11.2.5. Colorectal cancer |
| 11.2.6. Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Argentina |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029 |
| 11.5. Latin America Solid Tumor Market Dynamics - Trends |
| 12. Middle East and Africa Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.1.1. Antimetabolities |
| 12.1.2. MAbs |
| 12.1.3. XPO1 Inhibitor |
| 12.1.4. Mitotic Inhibitors |
| 12.1.5. Multikinase Inhibitors |
| 12.1.6. antineoplastics |
| 12.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Lung cancer |
| 12.2.2. Breast cancer |
| 12.2.3. Prostate cancer |
| 12.2.4. Cervical cancer |
| 12.2.5. Colorectal cancer |
| 12.2.6. Others |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Saudi Arabia |
| 12.3.2. GCC Countries |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029 |
| 12.5. MEA Solid Tumor Market Dynamics - Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Abbott Laboratories Inc. |
| 13.2.2. Biogen Inc. |
| 13.2.3. AstraZeneca PLC |
| 13.2.4. Boehringer Ingelheim GmbH |
| 13.2.5. Amgen Inc. |
| 13.2.6. Bristol-Myers Squibb Company |
| 13.2.7. Stemline Therapeutics, Inc. |
| 13.2.8. Baxter International Inc. |
| 13.2.9. Eli Lilly and Company |
| 13.2.10. F. Hoffmann-La Roche AG |
| 13.2.11. GlaxoSmithKline PLC |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
The solid tumor market key players are: Abbott Laboratories Inc., Biogen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Amgen Inc., Bristol-Myers Squibb Company, Stemline Therapeutics, Inc., Baxter International Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-La Roche AG
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
- Abbott Laboratories Inc.
- Biogen Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Amgen Inc.
- Bristol-Myers Squibb Company
- Stemline Therapeutics, Inc.
- Baxter International Inc.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Hoffmann-La Roche AG